In one of the studies retained in our systematic review, the authors created a predictive model to differentiate HER2-positive trastuzumab-treated breast cancer patients with a higher risk of relapse from those with a lower risk in a cohort of 53 patients[49]. Here, ERBB2 is linked to breast cancer.